Increased pentosidine, an advanced glycation end-product, in urine and tissue reflects disease activity in inflammatory bowel diseases.
BACKGROUND
Under inflammatory conditions with strong oxidative stresses, advanced glycation end-products (AGE), carbonyl compounds, are produced. The concentration of pentosidine, an AGE, reportedly correlates with complications of diabetes mellitus and worsening of rheumatoid arthritis, but its role in the pathogenesis of inflammatory bowel diseases (IBD) is unclear.


METHODS
Immunohistochemistry was performed with antibodies against pentosidine, and 8-OH-2-deoxyguanosine. The urinary concentration of pentosidine was also quantified by enzyme-linked immunosorbent assay method.


RESULTS
Pentosidine expression was up-regulated in the inflamed tissue of IBD. The expression of both pentosidine and 8-OH-2-deoxyguanosine was similar and increased in the inflamed epithelium and infiltrating cells (neutrophils and lymphocytes). The urinary concentration of pentosidine in active ulcerative colitis was significantly greater than that in inactive ulcerative colitis (0.12+/-0.15 vs 0.021+/-0.011 microg/mg of Cr, P<0.05), and was greater in active Crohn's disease than in inactive Crohn's disease (0.071+/-0.086 vs 0.039+/-0.023 microg/mg of Cr).


CONCLUSIONS
The urinary pentosidine level correlated with the activity of ulcerative colitis and may be a marker for disease activity in ulcerative colitis.
Kato
Shingo
S
Department of Gastroenterology and Hepatology, Saitama Medical Center, Saitama Medical University, Tsujido-machi, Kawagoe City, Saitama, Japan. skato@saitama-med.ac.jp
Itoh
Kazuro
K
Ochiai
Mitsuko
M
Iwai
Atsuhiro
A
Park
Yeongji
Y
Hata
Satoshi
S
Takeuchi
Kyoko
K
Ito
Masataka
M
Imaki
Junko
J
Miura
Soichiro
S
Yakabi
Koji
K
Kobayashi
Makio
M
D000080242:8-Hydroxy-2'-Deoxyguanosine; D000328:Adult; D001120:Arginine / Q000031:analogs & derivatives* / Q000032:analysis / Q000652:urine; D003093:Colitis, Ulcerative / Q000378:metabolism* / Q000652:urine; D003106:Colon / Q000737:chemistry*; D003424:Crohn Disease / Q000378:metabolism* / Q000652:urine; D003849:Deoxyguanosine / Q000031:analogs & derivatives / Q000032:analysis; D004797:Enzyme-Linked Immunosorbent Assay; D004847:Epithelial Cells / Q000737:chemistry; D005260:Female; D017127:Glycation End Products, Advanced / Q000032:analysis* / Q000652:urine; D006801:Humans; D007150:Immunohistochemistry; D008214:Lymphocytes / Q000737:chemistry; D008239:Lysine / Q000031:analogs & derivatives* / Q000032:analysis / Q000652:urine; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000737:chemistry; D012720:Severity of Illness Index; D015854:Up-Regulation; D055815:Young Adult
D017127:Glycation End Products, Advanced; D000080242:8-Hydroxy-2'-Deoxyguanosine; D001120:Arginine; C062187:pentosidine; D003849:Deoxyguanosine; D008239:Lysine